Pharsight

Drugs that contain Uridine Triacetate

1. Vistogard patents expiration

VISTOGARD IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5968914 BTG INTL Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Oct, 2016

(7 years ago)

US6258795 BTG INTL Acylated uridine and cytidine and uses thereof
Jul, 2023

(11 months ago)

US7776838 BTG INTL Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-104) Dec 11, 2022
Orphan Drug Exclusivity(ODE) Dec 11, 2022
New Product(NP) Dec 11, 2018
New Chemical Entity Exclusivity(NCE) Sep 04, 2020

NCE-1 date: 05 September, 2019

Market Authorisation Date: 11 December, 2015

Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...

Dosage: GRANULE;ORAL

More Information on Dosage

VISTOGARD family patents

Family Patents

2. Xuriden patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6258795 BTG INTL Acylated uridine and cytidine and uses thereof
Jul, 2023

(11 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Sep 04, 2022
Orphan Drug Exclusivity(ODE-98) Sep 04, 2022
New Chemical Entity Exclusivity(NCE) Sep 04, 2020

NCE-1 date: 05 September, 2019

Market Authorisation Date: 04 September, 2015

Treatment: NA

Dosage: GRANULE;ORAL

More Information on Dosage

XURIDEN family patents

Family Patents